Signos Raises $20 Million and Expands Weight Loss Partnership with Dexcom

Signos has raised $20 million in funding to support its work in weight loss and metabolic health. The company plans to use this investment to expand access to continuous glucose monitoring (CGM) technology. The funding round includes the expansion of an existing partnership with Dexcom. Signos uses Dexcom's CGM devices to provide users with personalized nutrition and exercise recommendations. With the new funds, the company aims to enhance its AI-powered platform and reach more users. Signos' CEO noted the growing importance of CGM technology in the weight loss market and described the partnership as strategic for both companies. The collaboration with Dexcom enables Signos to deliver real-time glucose data to its users, helping them optimize their food and activity choices. This is not investment advice.